Medscape is available in 5 Language Editions – Choose your Edition here.


Juvenile Dermatomyositis Workup

  • Author: Ann M Reed, MD; Chief Editor: Lawrence K Jung, MD  more...
Updated: Mar 19, 2015

Approach Considerations

Laboratory studies in the workup of juvenile dermatomyositis (JDM) include an erythrocyte sedimentation rate (ESR); muscle enzyme levels; lupus profile (ie, antinuclear antibody [ANA], extractable nuclear antigens [ENA]); and myositis-specific antibody assays such as antibodies against the aminoacyl t-RNA synthetases (ie, anti-Jo-1 antibody), antisignal recognition particle (anti-SRP antibody), and nuclear helicase (anti-Mi-2 antibody).[75]

Nailfold capillary microscopy may show end-row loop capillary loss and formation of bushy loops representing capillary dilatation and branching.[76]

A muscle biopsy is not usually performed to confirm the diagnosis of JDM, as it is for adult myositis. However, it is needed in the workup of juvenile polymyositis.

Magnetic resonance imaging (MRI) with T2-weighted fat suppression and short tau inversion recovery (STIR) is useful in the diagnostic workup because it reveals edema, a marker of muscle inflammation.

Muscle ultrasonography reveals increased muscle echogenicity, attenuation, and reduced bone surface echo. These changes are not specific for JDM, however, and this technique is not widely used.[77]

Electromyography (EMG) reveals a reduction of the motor unit action potentials in the proximal muscles and fibrillation potentials suggestive of fiber splitting, necrosis, and vacuolization. However, the EMG findings may be normal in approximately 19% of children.[30]


Tests of Inflammation and Autoimmunity

The ESR is commonly elevated in patients with JDM, but this finding is nonspecific.

levels of muscle enzymes such as aspartate aminotransferase, lactate dehydrogenase, creatine kinase, and aldolase may be elevated early in the disease course. Creatine kinase levels may initially be within the reference range in approximately 10-40% of patients and may return to normal within a few months of disease onset.[30, 66]

An elevated ANA level may be seen in approximately half of patients with JDM.[66] Generally, the extractable nuclear antigens (SSA, SSB, Sm, RNP, DNA) are negative.

Approximately 10% of patients have myositis-specific autoantibodies that define clinical subsets and serve as prognostic indicators of disease severity.[1, 78] These subsets are associated with different sets of signs and symptoms and, in some cases, onset at different times of year.

Rarely, the aminoacyl-transfer RNA (tRNA) synthetases such as Jo-1 (histidyl-tRNA synthetase), PL-12 (alanyl-tRNA synthetase), and PL-7 (threonyl-tRNA synthetase) have been associated with a spring onset of myositis, with the following clinical manifestations[79, 80] :

  • Nonerosive arthritis
  • Interstitial lung disease
  • Fever
  • Raynaud phenomenon
  • Mechanic’s hands.

The anti–signal recognition particle (SRP) autoantibodies are associated with an autumn onset and a severe, refractory myositis in less than 5% of JDM cases; in adults, the prognosis is poor, with a high mortality rate and cardiac involvement.[78, 81, 80] The anti-Mi-2 autoantibody may be seen in 5% of patients with mild to moderate JDM.[80]

The p155/140 kDa doublet protein, a myositis-associated autoantibody, has been identified in 29% of patients with JDM and may correlate with more extensive cutaneous involvement, including ulcerations and edema.[82, 83]


Magnetic Resonance Imaging

MRI with T2-weighted fat suppression and short tau inversion recovery (STIR) is useful in the diagnostic workup because it reveals edema, which is a marker of muscle inflammation. STIR findings must be interpreted cautiously, however, because patients with muscle dystrophies may have inflammation as well.[84]

The signal intensity from STIR may correlate with disease activity.[85] Areas of calcinosis or intramuscular fluid collections may be revealed. T1-weighted images reveal atrophy and fatty replacement from chronic damage.[86] MRI also helps in localizing an area for a potential muscle biopsy.[84]


Muscle Biopsy

A muscle biopsy is not usually performed to confirm the diagnosis of JDM, as it is for adult myositis; however, it is needed in the workup of juvenile polymyositis. Emerging data has suggested that muscle biopsy findings may be useful in predicting the clinical course and prognosis of JDM based on extensive active myopathic and arteriopathic changes.[87, 88]

If muscle biopsy is performed, a moderately weak muscle should be selected with specimens frozen for cryostat sections to perform histologic and enzyme histochemical stains and immunocytochemistry for major histocompatibility complex (MHC) antigens, immunophenotyping of T cells, and detection of cytokines and complement.[18]


Histologic Findings

Characteristic findings include perifascicular atrophy and a perivascular, mononuclear cell infiltrate with membrane attack complexes; swelling and occlusion of the capillary lumen; muscle degeneration; muscle regeneration; and infarcts. Necrosis of muscle fibers can occur in the fascicle periphery or in the center of the fascicle.[12, 18] CD4+ positive cells and B cells are seen in the perimysial and perivascular areas.

In contrast, in polymyositis, typical findings are invasion of non-necrotic fibers by CD8+ cytotoxic cells, activated macrophages with expression of major histocompatibility complex I, and inflammatory infiltrates in an endomysial distribution.[18]

An international consensus group has developed a scoring system for muscle biopsy findings in JDM. The system is based on 4 domains of change (inflammatory, vascular, muscle fiber, and connective tissue) and includes the following[88] :

  • CD3 + and CD 68 + endomysial, perimysial, and perivascular inflammation
  • Vascular changes, including capillary dropout, arterial findings, and infarction
  • Muscle fiber changes, such as MHC I overexpression, perifascicular atrophy, neonatal myosin, muscle degeneration, muscle regeneration, and necrosis
  • Endomysial and perimysial fibrosis

The consensus group suggests that if validated, the scoring system could be used in prospective studies to test which features of muscle pathology are prognostic of disease course or outcome.[88]


Assessment Scales

Assessment of muscle strength, physical endurance, and function is the primary means for determining clinical status and predicting outcomes in JDM. Several clinical outcome measures in JDM patients have been developed over the last decade to facilitate assessment of clinical response to treatment.

Physical function is measured by the Childhood Health Assessment Questionnaire (CHAQ), a reliable and validated instrument that correlates well with disease activity and functional outcomes. The CHAQ is a 30-item questionnaire that measures proximal muscle strength by assessing 8 areas of physical function, including dressing, grooming, eating, walking, hygiene, and the use of assistive devices.[89]

The Childhood Myositis Assessment Scale (CMAS) is a measure assessing muscle strength, functional capacity, and muscle endurance that has been developed and validated for JDM patients The 14-point scale measures activities such as timed neck flexion and sit-ups.[61]

The Disease Activity Scale assesses skin and muscle involvement.[90]

The cutaneous assessment tool (CAT), a 21-item test used to assess cutaneous manifestations in JDM, has been validated and correlated with skin disease damage scores.[91]

Contributor Information and Disclosures

Ann M Reed, MD Professor of Pediatrics and Medicine, Department of Pediatrics and Medicine, Chair of Pediatric Rheumatology, Research Chair of Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester

Ann M Reed, MD is a member of the following medical societies: American Academy of Pediatrics, Arthritis Foundation

Disclosure: Nothing to disclose.


Floranne Clayton Ernste, MD Assistant Professor of Medicine, Division of Rheumatology, Mayo Clinic College of Medicine

Floranne Clayton Ernste, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Rheumatology, Phi Beta Kappa

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Chief Editor

Lawrence K Jung, MD Chief, Division of Pediatric Rheumatology, Children's National Medical Center

Lawrence K Jung, MD is a member of the following medical societies: American Association for the Advancement of Science, American Association of Immunologists, American College of Rheumatology, Clinical Immunology Society, New York Academy of Sciences

Disclosure: Nothing to disclose.

Additional Contributors

Jayant Deodhar, MD Associate Professor in Pediatrics, BJ Medical College, India; Honorary Consultant, Departments of Pediatrics and Neonatology, King Edward Memorial Hospital, India

Disclosure: Nothing to disclose.

  1. Rider LG, Miller FW. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 1997 Aug. 23(3):619-55. [Medline].

  2. Rider LG, Miller FW. Idiopathic inflammatory muscle disease: clinical aspects. Baillieres Best Pract Res Clin Rheumatol. 2000 Mar. 14(1):37-54. [Medline].

  3. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975 Feb 13. 292(7):344-7. [Medline].

  4. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975 Feb 20. 292(8):403-7. [Medline].

  5. Brown VE, Pilkington CA, Feldman BM, Davidson JE,. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford). 2006 Aug. 45(8):990-3. [Medline].

  6. Spencer CH, Hanson V, Singsen BH, Bernstein BH, Kornreich HK, King KK. Course of treated juvenile dermatomyositis. J Pediatr. 1984 Sep. 105(3):399-408. [Medline].

  7. Constantin T, Ponyi A, Orban I, Molnar K, Derfalvi B, Dicso F. National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary--clinical characteristics and disease course of 44 patients with juvenile dermatomyositis. Autoimmunity. 2006 May. 39(3):223-32. [Medline].

  8. Gerami P, Walling HW, Lewis J, Doughty L, Sontheimer RD. A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol. 2007 Oct. 157(4):637-44. [Medline].

  9. Hiketa T, Matsumoto Y, Ohashi M, Sasaki R. Juvenile dermatomyositis: a statistical study of 114 patients with dermatomyositis. J Dermatol. 1992 Aug. 19(8):470-6. [Medline].

  10. Engel AG, Arahata K, Emslie-Smith A. Immune effector mechanisms in inflammatory myopathies. Res Publ Assoc Res Nerv Ment Dis. 1990. 68:141-57. [Medline].

  11. Engel AG, Arahata K. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol. 1986 Jul. 17(7):704-21. [Medline].

  12. Crowe WE, Bove KE, Levinson JE, Hilton PK. Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum. 1982 Feb. 25(2):126-39. [Medline].

  13. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003 Sep 20. 362(9388):971-82. [Medline].

  14. Li CK, Varsani H, Holton JL, Gao B, Woo P, Wedderburn LR. MHC Class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol. 2004 Mar. 31(3):605-9. [Medline].

  15. Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology. 2007 Nov 20. 69(21):2008-19. [Medline].

  16. Lopez de Padilla CM, Vallejo AN, McNallan KT, Vehe R, Smith SA, Dietz AB. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum. 2007 May. 56(5):1658-68. [Medline].

  17. Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med. 1986 Feb 6. 314(6):329-34. [Medline].

  18. Dalakas MC. Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin North Am. 2002 Nov. 28(4):779-98, vi. [Medline].

  19. Chevrel G, Page G, Granet C, Streichenberger N, Varennes A, Miossec P. Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol. 2003 Apr. 137(1-2):125-33. [Medline].

  20. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature. 2008 Jun 19. 453(7198):1051-7. [Medline].

  21. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol. 2008 May. 8(5):337-48. [Medline].

  22. López De Padilla CM, Vallejo AN, Lacomis D, McNallan K, Reed AM. Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum. 2009 Apr. 60(4):1160-72. [Medline].

  23. Tezak Z, Hoffman EP, Lutz JL, Fedczyna TO, Stephan D, Bremer EG. Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol. 2002 Apr 15. 168(8):4154-63. [Medline]. [Full Text].

  24. Nagaraju K, Rider LG, Fan C, Chen YW, Mitsak M, Rawat R, et al. Endothelial cell activation and neovascularization are prominent in dermatomyositis. J Autoimmune Dis. 2006 Feb 20. 3:2. [Medline]. [Full Text].

  25. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 2005. 23:275-306. [Medline].

  26. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005 May. 57(5):664-78. [Medline].

  27. McNiff JM, Kaplan DH. Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus. J Cutan Pathol. 2008 May. 35(5):452-6. [Medline].

  28. Niewold TB, Wu SC, Smith M, Morgan GA, Pachman LM. Familial aggregation of autoimmune disease in juvenile dermatomyositis. Pediatrics. 2011 May. 127(5):e1239-46. [Medline]. [Full Text].

  29. Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol. 1995 Aug. 34(8):732-6. [Medline].

  30. Pachman LM, Hayford JR, Chung A, Daugherty CA, Pallansch MA, Fink CW. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol. 1998 Jun. 25(6):1198-204. [Medline].

  31. Massa M, Costouros N, Mazzoli F, et al. Self Epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis Rheum. 2002. 46(11):3015-3025.

  32. Christensen ML, Pachman LM, Schneiderman R, Patel DC, Friedman JM. Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis. Arthritis Rheum. 1986 Nov. 29(11):1365-70. [Medline].

  33. Chevrel G, Calvet A, Belin V, Miossec P. Dermatomyositis associated with the presence of parvovirus B19 DNA in muscle. Rheumatology (Oxford). 2000 Sep. 39(9):1037-9. [Medline]. [Full Text].

  34. Lewkonia RM, Horne D, Dawood MR. Juvenile dermatomyositis in a child infected with human parvovirus B19. Clin Infect Dis. 1995 Aug. 21(2):430-2. [Medline].

  35. Zampieri S, Ghirardello A, Iaccarino L, Briani C, Sarzi-Puttini P, Atzeni F. Polymyositis-dermatomyositis and infections. Autoimmunity. 2006 May. 39(3):191-6. [Medline].

  36. Albani, S. Infection and molecular mimicry in autoimmune diseases of childhood. Clin Exp Rheumatol. 1994. 12 (Suppl 10):S35-41.

  37. Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007 Jan-Feb. 13(1-2):59-68. [Medline]. [Full Text].

  38. Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 2007 Nov. 56(11):3784-92. [Medline]. [Full Text].

  39. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005 May. 57(5):664-78. [Medline].

  40. Dourmishev AL, Dourmishev LA. Dermatomyositis and drugs. Adv Exp Med Biol. 1999. 455:187-91. [Medline].

  41. Kass E, Straume S, Mellbye OJ, Munthe E, Solheim BG. Dermatomyositis associated with BCG vaccination. Scand J Rheumatol. 1979. 8(3):187-91. [Medline].

  42. Adams C, August CS, Maguire H, Sladky JT. Neuromuscular complications of bone marrow transplantation. Pediatr Neurol. 1995 Jan. 12(1):58-61. [Medline].

  43. Reed AM, Pachman L, Ober C. Molecular genetic studies of major histocompatibility complex genes in children with juvenile dermatomyositis: increased risk associated with HLA-DQA1 *0501. Hum Immunol. 1991 Dec. 32(4):235-40. [Medline].

  44. Reed AM, Stirling JD. Association of the HLA-DQA1*0501 allele in multiple racial groups with juvenile dermatomyositis. Hum Immunol. 1995 Nov. 44(3):131-5. [Medline].

  45. Mamyrova G, O'Hanlon TP, Monroe JB, Carrick DM, Malley JD, Adams S, et al. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum. 2006 Dec. 54(12):3979-87. [Medline]. [Full Text].

  46. Reed AM, McNallan K, Wettstein P, Vehe R, Ober C. Does HLA-dependent chimerism underlie the pathogenesis of juvenile dermatomyositis?. J Immunol. 2004 Apr 15. 172(8):5041-6. [Medline]. [Full Text].

  47. Reed AM, Picornell YJ, Harwood A, Kredich DW. Chimerism in children with juvenile dermatomyositis. Lancet. 2000 Dec 23-30. 356(9248):2156-7. [Medline].

  48. Artlett CM, Ramos R, Jiminez SA, Patterson K, Miller FW, Rider LG. Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Childhood Myositis Heterogeneity Collaborative Group. Lancet. 2000 Dec 23-30. 356(9248):2155-6. [Medline].

  49. Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum. 2000 Oct. 43(10):2368-77. [Medline].

  50. Fedczyna TO, Lutz J, Pachman LM. Expression of TNFalpha by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNFalpha-308A allele. Clin Immunol. 2001 Aug. 100(2):236-9. [Medline].

  51. Rider LG, Artlett CM, Foster CB, Ahmed A, Neeman T, Chanock SJ, et al. Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. Clin Exp Immunol. 2000 Jul. 121(1):47-52. [Medline]. [Full Text].

  52. Kelly JC. Juvenile Dermatomyositis May Be Triggered by UV Exposure. Medscape Medical News. Available at Accessed: March 19, 2015.

  53. Shah M, Targoff IN, Rice MM, Miller FW, Rider LG. Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. Arthritis Rheum. 2013 Jul. 65(7):1934-41. [Medline]. [Full Text].

  54. Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 2003 Jun 15. 49(3):300-5. [Medline].

  55. Pachman LM, Lipton R, Ramsey-Goldman R, Shamiyeh E, Abbott K, Mendez EP. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum. 2005 Apr 15. 53(2):166-72. [Medline].

  56. Bitnum S, Daeschner CW Jr, Travis LB, Dodge WF, Hopps HC. Dermatomyositis. J Pediatrics. 1964. 64:101-31.

  57. Huber AM, Feldman BM. Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going?. Curr Rheumatol Rep. 2005/12. 7(6):441-6.

  58. Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum. 2000 Mar. 43(3):541-9. [Medline].

  59. Miller LC, Michael F, Kim Y. Childhood dermatomyositis: Clinical course and long-term follow-up. Clin Pediatr. 1987. 26(11):5661-6.

  60. Taieb A, Guichard C, Salamon R, Maleville J. Prognosis in juvenile dermatopolymyositis: a cooperative retrospective study of 70 cases. Pediatr Dermatol. 1985 Jul. 2(4):275-81. [Medline].

  61. Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum. 2004 May. 50(5):1595-603. [Medline].

  62. Rider LG. Calcinosis in juvenile dermatomyositis: pathogenesis and current therapies. Pediatric Rheumatology Online Journal. 2003. 1(2):[Full Text].

  63. Boulman N, Slobodin G, Rozenbaum M, Rosner I. Calcinosis in rheumatic diseases. Semin Arthritis Rheum. 2005 Jun. 34(6):805-12. [Medline].

  64. Hundley JL, Carroll CL, Lang W, Snively B, Yosipovitch G, Feldman SR. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. J Am Acad Dermatol. 2006 Feb. 54(2):217-20. [Medline].

  65. Sallum AM, Pivato FC, Doria-Filho U, et al. Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr (Rio J). 2008. 84(1):68-74.

  66. Peloro TM, Miller OF 3rd, Hahn TF, Newman ED. Juvenile dermatomyositis: a retrospective review of a 30-year experience. J Am Acad Dermatol. 2001 Jul. 45(1):28-34. [Medline].

  67. Braunstein EM, White SJ. Pneumatosis intestinalis in dermatomyositis. Br J Radiol. 1980 Oct. 53(634):1011-2. [Medline].

  68. Stefanski JC, Shetty AK. Abdominal pain in a girl with juvenile dermatomyositis. Clin Pediatr (Phila). 1998. 37(9):561-563.

  69. Santmyire-Rosenberger B, Dugan EM. Skin involvement in dermatomyositis. Curr Opin Rheumatol. 2003 Nov. 15(6):714-22. [Medline].

  70. Smith RL, Sundberg J, Shamiyah E, Dyer A, Pachman LM. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol. 2004 Aug. 31(8):1644-9. [Medline].

  71. García-Patos V, Bartralot R, Fonollosa V, Arnal C, Boronat M, Gelpí C. Childhood sclerodermatomyositis: report of a case with the anti-PM/Scl antibody and mechanic's hands. Br J Dermatol. 1996 Oct. 135(4):613-6. [Medline].

  72. Pachman LM, Veis A, Stock S, Abbott K, Vicari F, Patel P, et al. Composition of calcifications in children with juvenile dermatomyositis: association with chronic cutaneous inflammation. Arthritis Rheum. 2006 Oct. 54(10):3345-50. [Medline]. [Full Text].

  73. Wananukul S, Pongprasit P, Wattanakrai P. Calcinosis cutis presenting years before other clinical manifestations of juvenile dermatomyositis: report of two cases. Australas J Dermatol. 1997 Nov. 38(4):202-5. [Medline].

  74. Blane CE, White SJ, Braunstein EM, Bowyer SL, Sullivan DB. Patterns of calcification in childhood dermatomyositis. AJR Am J Roentgenol. 1984 Feb. 142(2):397-400. [Medline].

  75. Targoff IN. Myositis specific autoantibodies. Curr Rheumatol Rep. 2006 Jun. 8(3):196-203. [Medline].

  76. Dolezalova P, Young SP, Bacon PA, Southwood TR. Nailfold capillary microscopy in healthy children and in childhood rheumatic diseases: a prospective single blind observational study. Ann Rheum Dis. 2003 May. 62(5):444-9. [Medline]. [Full Text].

  77. Lamminen A, Jääskeläinen J, Rapola J, Suramo I. High-frequency ultrasonography of skeletal muscle in children with neuromuscular disease. J Ultrasound Med. 1988 Sep. 7(9):505-9. [Medline].

  78. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogenous patient groups. Medicine (Baltimore). 1991. 70(6):360-74.

  79. Chmiel JF, Wessel HU, Targoff IN, Pachman LM. Pulmonary fibrosis and myositis in a child with anti-Jo-1 antibody. J Rheumatol. 1995 Apr. 22(4):762-5. [Medline].

  80. Rider LG, Miller FW, Targoff IN, Sherry DD, Samayoa E, Lindahl M. A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthritis Rheum. 1994 Oct. 37(10):1534-8. [Medline].

  81. Leff RL, Burgess SH, Miller FW, Love LA, Targoff IN, Dalakas MC. Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1 and anti-signal recognition particle autoantibodies. Arthritis Rheum. 1991 Nov. 34(11):1391-6. [Medline].

  82. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006. 54(11):3682-3689.

  83. Gunawardena H, Wedderburn LR, North J, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford). 2008. 47(3):324-328.

  84. Chan WP, Liu GC. MR imaging of primary skeletal muscle diseases in children. AJR Am J Roentgenol. 2002 Oct. 179(4):989-97. [Medline]. [Full Text].

  85. Fraser DD, Frank JA, Dalakas M, Miller FW, Hicks JE, Plotz P. Magnetic resonance imaging in the idiopathic inflammatory myopathies. J Rheumatol. 1991 Nov. 18(11):1693-700. [Medline].

  86. Summers RM, Brune AM, Choyke PL, Chow CK, Patronas NJ, Miller FW. Juvenile idiopathic inflammatory myopathy: exercise-induced changes in muscle at short inversion time inversion-recovery MR imaging. Radiology. 1998 Oct. 209(1):191-6. [Medline].

  87. Miles L, Bove KE, Lovell D, Wargula JC, Bukulmez H, Shao M. Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients. Arthritis Rheum. 2007 Oct 15. 57(7):1183-91. [Medline].

  88. Wedderburn LR, Varsani H, Li CK, et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis:a tool for potential use in clinical trials. Arthritis Rheum. 2007. 57(7):1192-201.

  89. Feldman BM, Ayling-Campos A, Luy L, Stevens D, Silverman ED, Laxer RM. Measuring disability in juvenile dermatomyositis: validity of the childhood health assessment questionnaire. J Rheumatol. 1995 Feb. 22(2):326-31. [Medline].

  90. Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, Lipton R. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr. 2006 Feb. 148(2):247-53. [Medline].

  91. Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS. Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. Arthritis Rheum. 2008 Feb 15. 59(2):214-21. [Medline].

  92. Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford). 2004. 43(4):491-496.

  93. Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat. 2004 Jan. 15(1):35-9. [Medline].

  94. Zieglschmid-Adams ME, Pandya AG, Cohen SB, Sontheimer RD. Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol. 1995 May. 32(5 Pt 1):754-7. [Medline].

  95. Ichiki Y, Akiyama T, Shimozawa N, Suzuki Y, Kondo N, Kitajima Y. An extremely severe case of cutaneous calcinosis with juvenile dermatomyositis, and successful treatment with diltiazem. Br J Dermatol. 2001 Apr. 144(4):894-7. [Medline].

  96. Stringer E, Feldman BM. Advances in the treatment of juvenile dermatomyositis. Curr Opin Rheumatol. 2006 Sep. 18(5):503-6. [Medline].

  97. Huang JL. Long-term prognosis of patients with juvenile dermatomyositis initially treated with intravenous methylprednisolone pulse therapy. Clin Exp Rheumatol. 1999 Sep-Oct. 17(5):621-4. [Medline].

  98. Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum. 2005 Nov. 52(11):3570-8. [Medline].

  99. Reiff A, Rawlings DJ, Shaham B, Franke E, Richardson L, Szer IS. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol. 1997 Dec. 24(12):2436-43. [Medline].

  100. Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford). April 2008. [Full Text].

  101. Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum. 2007 Sep. 56(9):3107-11. [Medline].

  102. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial. Arthritis Rheum. 2012 Nov 2. [Medline].

  103. Alexanderson H, Dastmalchi M, Esbjörnsson-Liljedahl M, Opava CH, Lundberg IE. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum. 2007 Jun 15. 57(5):768-77. [Medline].

  104. Stewart WA, Acott PD, Salisbury SR, Lang BA. Bone mineral density in juvenile dermatomyositis: assessment using dual x-ray absorptiometry. Arthritis Rheum. 2003 Aug. 48(8):2294-8. [Medline].

  105. Perez MD, Abrams SA, Koenning G, Stuff JE, O'Brien KO, Ellis KJ. Mineral metabolism in children with dermatomyositis. J Rheumatol. 1994 Dec. 21(12):2364-9. [Medline].

  106. Huemer C, Kitson H, Malleson PN, Sanderson S, Huemer M, Cabral DA. Lipodystrophy in patients with juvenile dermatomyositis--evaluation of clinical and metabolic abnormalities. J Rheumatol. 2001 Mar. 28(3):610-5. [Medline].

A characteristic, violaceous rash is present over the eyelids with periorbital edema in a child with juvenile dermatomyositis.
Gottron papules are present over the metacarpophalangeal joints and proximal interphalangeal joints in a child with juvenile dermatomyositis.
An erythematous "V-neck" rash is present on the upper chest of a child with juvenile dermatomyositis.
An erythematous, violaceous, scaly rash is present over extensor surfaces in a child with juvenile dermatomyositis.
Calcinosis cutis over the left elbow in a patient with juvenile dermatomyositis for 16 years.
Diffuse sheets of calcification extending along the myofascial planes of the gluteus muscles and the anterior and posterior muscles of the thigh in a child with juvenile dermatomyositis.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.